AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28153042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites (provider/staff training sessions and patient education materials)
Number of subjects: 408
Study 28153042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites (provider/staff training sessions)
Number of subjects: 408
Study 28153042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites (patient education materials)
Number of subjects: 408
Study 28153042 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 408
Study 28153042 — intervention group
Group type: COMPARATOR
Intervention: Usual care sites
Number of subjects: 408
Study 28153814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app (My Meal Mate) - recorded ≥129 days
Number of subjects: 43
Study 28153814 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone app (My Meal Mate) - recorded ≤42 days
Number of subjects: 43
Study 28153861 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy for traumatic meniscal tears
Number of subjects: 397
Study 28153861 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy for degenerative meniscal tears
Number of subjects: 397
Study 28153869 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28153957 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of the unknown primary tumor
Number of subjects: 0
Study 28153990 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week angina frequency
Number of subjects: 11595
Study 28153990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year angina frequency
Number of subjects: 11595
Study 28153990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year unplanned rehospitalization
Number of subjects: 11595
Study 28153990 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week angina as a predictor of rehospitalization
Number of subjects: 11595
Study 28155045 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib (selective aurora kinase A inhibitor)
Number of subjects: 22
Study 28155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted psychoeducation (CaPE) plus Treatment As Usual (TAU)
Number of subjects: 34
Study 28155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted psychoeducation (CaPE)
Number of subjects: 34
Study 28155203 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 34
Study 28157063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative amounts of harmful excipients (ethanol, propylene glycol, benzyl alcohol, parabens, acesulfame p, aspartame, glycerol, sorbitol, polysorbate-80) administered during hospitalization.
Number of subjects: 0
Study 28157173 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel patch test in NCWS patients
Number of subjects: 60
Study 28157173 — intervention group
Group type: COMPARATOR
Intervention: Control group (80 age- and sex-matched subjects with functional gastrointestinal symptoms)
Number of subjects: 60
Study 28157173 — intervention group
Group type: EXPERIMENTAL
Intervention: NCWS patients with nickel allergy
Number of subjects: 60
Study 28157218 — intervention group
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Number of subjects: 0
Study 28157218 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28158311 — intervention group
Group type: EXPERIMENTAL
Intervention: BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, administered as 5 doses totaling 43 mg/kg BW over a 7-week period.
Number of subjects: 4
Study 28158395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with S. Paratyphi A at a dose of 1-5 × 10^3 CFU
Number of subjects: 20
Study 28158395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge with S. Paratyphi A at a dose of 0.5-1 × 10^3 CFU
Number of subjects: 20
Study 28158395 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment started when prespecified diagnostic criteria were met or at day 14 postchallenge
Number of subjects: 20
Study 28158463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 6 mg/kg Q2W (N = 3)
Number of subjects: 15
Study 28158463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg Q2W (N = 6)
Number of subjects: 15
Study 28158463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 10 mg/kg Q3W (N = 6)
Number of subjects: 15
Study 28158504 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) including tenofovir disoproxil fumarate
Number of subjects: 463
Study 28158504 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 463
Study 28158551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent reactivations of herpesviruses (CMV, EBV, HHV-6, HSV-1, HSV-2, VZV)
Number of subjects: 329
Study 28158551 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent CMV and EBV reactivations
Number of subjects: 329
Study 28159013 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume
Number of subjects: 19
Study 28159013 — intervention group
Group type: COMPARATOR
Intervention: Low tidal volume
Number of subjects: 19
Study 28159014 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted esophagectomy (RE)
Number of subjects: 50
Study 28159014 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 50
Study 28159192 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis (50-60 IU/kg) once per week, adjusted to ≤100 IU/kg per infusion or up to two times per week as needed
Number of subjects: 30
Study 28159192 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc prophylaxis
Number of subjects: 30
Study 28159192 — intervention group
Group type: EXPERIMENTAL
Intervention: rFIXFc
Number of subjects: 30
Study 28159311 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose/rhamnose enterally on study days 1, 8, and 15
Number of subjects: 43
Study 28159311 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastmilk feeding
Number of subjects: 43
Study 28159311 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 43
Study 28159311 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed initiation of feeding ≥4 days
Number of subjects: 43
Study 28159465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node mapping with complete pelvic lymphadenectomy
Number of subjects: 385
Study 28159465 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node mapping
Number of subjects: 385
Study 28159490 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel (75mg/m² every 3 weeks for 6 cycles)
Number of subjects: 790
Study 28159490 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 790
Study 28159490 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 790
Study 28159511 — intervention group
Group type: EXPERIMENTAL
Intervention: Reslizumab IV 3 mg/kg every 4 weeks
Number of subjects: 273
Study 28159511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 28159512 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB) therapy
Number of subjects: 25
Study 28159512 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil therapy
Number of subjects: 25
Study 28159590 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for antidepressant efficacy
Number of subjects: 3756
Study 28159590 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS from MDD and schizophrenia
Number of subjects: 3756
Study 28159590 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified by antidepressant (escitalopram or citalopram)
Number of subjects: 3756
Study 28159590 — intervention group
Group type: EXPERIMENTAL
Intervention: PRS between pharmacogenetic studies
Number of subjects: 3756
Study 28159590 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to MDD or schizophrenia
Number of subjects: 3756
Study 28159728 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of flaxseed lignan (secoisolariciresinol diglucoside; SDG) daily
Number of subjects: 32
Study 28159728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28159731 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAP II (single-channel EEG device)
Number of subjects: 40
Study 28159731 — intervention group
Group type: COMPARATOR
Intervention: BIS VISTA (dual-channel EEG device)
Number of subjects: 40
Study 28159823 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of serum acetyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164
Study 28159823 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of serum octanoyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164
Study 28159823 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of serum palmitoyl-carnitines (quartile 4 vs quartile 1)
Number of subjects: 4164
Study 28159823 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum even-chained acylcarnitines
Number of subjects: 4164
Study 28159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfatinib formulation 2 (50 and 200 mg capsules)
Number of subjects: 77
Study 28159938 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfatinib (300 mg recommended phase II dose)
Number of subjects: 77
Study 28160194 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Troland stimulus
Number of subjects: 18
Study 28160194 — intervention group
Group type: COMPARATOR
Intervention: Constant luminance stimulus
Number of subjects: 18
Study 28160351 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 129
Study 28160351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 129
Study 28160351 — intervention group
Group type: EXPERIMENTAL
Intervention: Average lifetime definition of rapid cycling
Number of subjects: 129
Study 28160351 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-IV definition of rapid cycling
Number of subjects: 129
Study 28160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI (obese vs. normal weight)
Number of subjects: 37
Study 28160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI (overweight and obese vs. normal weight)
Number of subjects: 37
Study 28160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI and sex of infant
Number of subjects: 37
Study 28160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Month 1 leptin levels
Number of subjects: 37
Study 28160457 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI, infant sex, and stage of lactation
Number of subjects: 37
Study 28160528 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 2783
Study 28160528 — intervention group
Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 2783
Study 28161120 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (ramp-up treatment 20-200 mg) with posaconazole (20 mg)
Number of subjects: 12
Study 28161120 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (reduced dose)
Number of subjects: 12
Study 28161570 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (Shanchol)
Number of subjects: 900
Study 28161570 — intervention group
Group type: COMPARATOR
Intervention: No exposure to oral cholera vaccine
Number of subjects: 900
Study 28162825 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent live attenuated influenza vaccine (Q/LAIV)
Number of subjects: 62040
Study 28162825 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 62040
Study 28162825 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV) recipients
Number of subjects: 62040
Study 28163319 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade complementary food
Number of subjects: 132
Study 28163319 — intervention group
Group type: COMPARATOR
Intervention: Commercial complementary food
Number of subjects: 132
Study 28163319 — intervention group
Group type: COMPARATOR
Intervention: Both homemade and commercial complementary food
Number of subjects: 132
Study 28163748 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction diet and optimal physical activity
Number of subjects: 272
Study 28163748 — intervention group
Group type: COMPARATOR
Intervention: Conventional drug treatment with weight loss
Number of subjects: 272
Study 28163786 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of the WHO checklist
Number of subjects: 0
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 1355
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in evidence-based cessation assistance
Number of subjects: 1355
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopting strictly enforced smoke-free home policies
Number of subjects: 1355
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopting strictly enforced smoke-free car policies
Number of subjects: 1355
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing that being a smoker got in the way of being a parent
Number of subjects: 1355
Study 28163788 — intervention group
Group type: EXPERIMENTAL
Intervention: Believing that thirdhand smoke is harmful to children
Number of subjects: 1355
Study 28164014 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) performed in 175 Russian PCI centers; 531 PCI per 1,000,000 population; 101,451 stents placed (1.37 stents per PCI; 48,057 drug-eluting stents).
Number of subjects: 175
Study 28164014 — intervention group
Group type: EXPERIMENTAL
Intervention: National policy efforts leading to a documented 27% 10-year decline in CV mortality.
Number of subjects: 175
Study 28164014 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in trial population (86.7%).
Number of subjects: 175
Study 28164014 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevalence in trial population (16.7%); BMI in trial was 28.4.
Number of subjects: 175
Study 28164014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in trial population (86.1%).
Number of subjects: 175
Study 28164367 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hyperglycaemia (> 11.1 mmol/l) in people without diabetes
Number of subjects: 7132
Study 28164367 — intervention group
Group type: COMPARATOR
Intervention: People with diabetes
Number of subjects: 7132
Study 28164367 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 7132
Study 28165653 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted biopsy (TB)
Number of subjects: 161
Study 28165653 — intervention group
Group type: COMPARATOR
Intervention: Systematic biopsy (SB)
Number of subjects: 161
Study 28166744 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 19
Study 28166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria treatment or any other medication within 14 days
Number of subjects: 2421
Study 28166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide spray within 7 days
Number of subjects: 2421
Study 28166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mosquito nets
Number of subjects: 2421
Study 28166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, rural residence, natural floor, grass/palm roof, unavailability of electricity
Number of subjects: 2421
Study 28166794 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection prevalence
Number of subjects: 2421
Study 28166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-flight evaluation with spirometry and arterial oxygen tension (PaO2) measurements.
Number of subjects: 30
Study 28166839 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing as a predictive measure.
Number of subjects: 30
Study 28167156 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 75 mg
Number of subjects: 2814
Study 28167156 — intervention group
Group type: EXPERIMENTAL
Intervention: Eluxadoline 100 mg
Number of subjects: 2814
Study 28167156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2814
Study 28167411 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemisphere stroke survivors
Number of subjects: 265
Study 28167411 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 265
Study 28168735 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod (IMQ) pretreatment with NB-UVB therapy
Number of subjects: 0
Study 28168735 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB therapy alone
Number of subjects: 0
Study 28168845 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug eluting stents (DES)
Number of subjects: 311
Study 28168845 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding DAPT drawbacks
Number of subjects: 311
Study 28169043 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative adaptive radiotherapy (ART)
Number of subjects: 22
Study 28169043 — intervention group
Group type: COMPARATOR
Intervention: Conformal and conventional plans
Number of subjects: 22
Study 28169043 — intervention group
Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 22
Study 28169974 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological parenteral treatment
Number of subjects: 79
Study 28169974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbiological oral treatment
Number of subjects: 79
Study 28169974 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 79
Study 28171703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 865
Study 28171703 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 865
Study 28173776 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 0
Study 28173776 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28173784 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive approach integrating clinical and functional status-based pathology and adapted rehabilitation prescription
Number of subjects: 0
Study 28173814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification (donor oocytes)
Number of subjects: 204
Study 28173814 — intervention group
Group type: COMPARATOR
Intervention: Slow-freezing (donor oocytes)
Number of subjects: 204
Study 28173814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification (autologous oocytes)
Number of subjects: 204
Study 28173852 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular stool testing (Cologuard® and FIT)
Number of subjects: 4000
Study 28173852 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy surveillance
Number of subjects: 4000
Study 28174148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam for conscious sedation
Number of subjects: 148
Study 28174148 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 148
Study 28174174 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher observed particle concentration (highest residual quartile)
Number of subjects: 27533
Study 28174174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower observed particle concentration (lowest residual quartile)
Number of subjects: 27533
Study 28174174 — intervention group
Group type: COMPARATOR
Intervention: Agreement between markers (middle quartiles)
Number of subjects: 27533
Study 28174191 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3) for 10 minutes after intravenous injection of microbubble contrast agents (2×10)
Number of subjects: 2
Study 28174191 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (1.3 MHz, mechanical index 1.3)
Number of subjects: 2
Study 28174292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin spray
Number of subjects: 21
Study 28174292 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 21
Study 28174487 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) using oxaliplatin plus capecitabine (CapOX)
Number of subjects: 47
Study 28174664 — intervention group
Group type: EXPERIMENTAL
Intervention: InterWalk Fitness Test
Number of subjects: 0
Study 28176442 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 574
Study 28176442 — intervention group
Group type: COMPARATOR
Intervention: Control (no Remote Monitoring)
Number of subjects: 574
Study 28177169 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-based classification algorithm for predicting likelihood of being CT+
Number of subjects: 720
Study 28177438 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4023 (MVA-FCU1) at doses of 107, 108, or 4 × 108 p.f.u. via intratumoral injection
Number of subjects: 16
Study 28177438 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FC (flucytosine) at a dose of 200 mg/kg/day for 14 days
Number of subjects: 16
Study 28177438 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4023/5-FC combination
Number of subjects: 16
Study 28177438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with TG4023 and 5-FC
Number of subjects: 16
Study 28177438 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4023 (MVA-FCU1)
Number of subjects: 16
Study 28177448 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention in healthy habits
Number of subjects: 0
Study 28177448 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28178062 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment (face-to-face discussions at obstetric appointments)
Number of subjects: 0
Study 28178062 — intervention group
Group type: COMPARATOR
Intervention: Indirect recruitment (flyers and general emails)
Number of subjects: 0
Study 28178062 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal care provider support
Number of subjects: 0
Study 28178345 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + ONO/GS-4059
Number of subjects: 0
Study 28178345 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + GSK2334470 or MK-2206
Number of subjects: 0